Research programme: adenosine receptor modulators - Palobiofarma

Drug Profile

Research programme: adenosine receptor modulators - Palobiofarma

Alternative Names: e compound; PBF 1350; PBF 1472; PBF 1509; PBF-1129; PBF-1250; PBF-695; PBF-942

Latest Information Update: 28 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Palobiofarma
  • Class
  • Mechanism of Action Adenosine A1 receptor agonists; Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Adenosine A3 receptor antagonists; Phosphodiesterase 10A inhibitors; Plasminogen activator inhibitors; Purinergic P1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atrial fibrillation; Glaucoma; Psychiatric disorders

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Idiopathic thrombocytopenic purpura; IgA nephropathy; Lung cancer
  • Discontinued Atrial fibrillation; Glaucoma; Psychiatric disorders

Most Recent Events

  • 28 Jan 2016 Discontinued - Preclinical for Glaucoma in Spain (PO)
  • 28 Jan 2016 Discontinued - Preclinical for Psychiatric disorders in Spain (PO)
  • 28 Jan 2016 Discontinued for Atrial fibrillation in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top